Table 4:
Recent publications evaluating efficacy and safety of microwave ablation for the treatment of localized renal cell carcinoma.
| Study | Year | Experimental design | Intervention | Patient population | Number of patients | Outcomes | Mean/Median follow-up | Conclusions |
|---|---|---|---|---|---|---|---|---|
| Olweny et al. |
2012 | Retrospective Single institution |
RFAvs PN | Biopsy-proven, T1a RCC | RFA cohort = 37 PN cohort = 37 |
OS CSS RFS DFS MFS |
RFA Median = 6.5 years PN Median = 6.1 years |
5-yr OS = 97.2 vs 100%; P = 0.31 5-yr CSS = 97.2 vs 100%; P = 0.31 5-yr DFS = 89.2 vs 89.2%; P = 0.78 5-yr RFS = 91.7 vs 94.7%; P = 0.96 5-yr MFS = 97.2 vs 91.5%; P = 0.35 |
| Psutka et al. |
2013 | Retrospective Single institution |
RFA | cT1 RCC | RFA cohort = 185 | RFS MFS CSS DFS OS |
Median = 6.43 years | 5-yr RFS = 95.2% 5-yr MFS =99.4% 5-yr CSS = 99.4% 5-yr DFS =87.6% 5-yr OS = 73.3% 10-yr RFS T1a = 93.2% |
| Chang et al. |
2015 | Retrospective Single institution |
RFA vs PN | Biopsy-proven, T1b RCC | RFA cohort = 27 PN cohort = 29 |
OS CSS DFS |
RFA Mean = 65.9 months PN Mean = 70.2 months |
5-yr OS = 85.5 vs 96.6%; P = 0.14 5-yr CSS = 92.6 vs 96.6; P = 0.49 5-yr DFS = 81.0 vs 89.7%; P = 0.36 |
| Ji et al. | 2016 | Retrospective Single institution |
RFA vs PN | Biopsy-proven, T1a RCC | RFA cohort = 105 PN cohort = 74 |
OS CSS DFS |
RFA = Median 78 months PN = Median 82 months |
5-yr OS = 93.3 vs 94.6%; P > 0.05 5-yr CSS = 98.0 vs 98.5; P > 0.05 5-yr DFS = 97.1 vs 97.3%; P > 0.05 |
| Andrews et al. | 2019 | Retrospective Single institution |
RFA vs PN vs PCA | Clinical T1 RCC | RFA cohort = 180 PN cohort = 1055 PCA cohort = 187 |
CSS | RFA Median = 7.5 years PN Median = 9.4 years Cryo Median = 6.3 years |
5-yr CSS cT1a = 95.6 vs 99.3 vs 100% 5-yr CSS cT1b = N/A vs 98% vs 91% |
| Park et al. | 2019 | Retrospective Single institution |
RFA vs PN | Biopsy-proven, T1a RCC |
RFA cohort = 62 | OS | RFA Mean = 60 months | 5-yr OS = 98.4 vs 100%; P = 0.360 |
| Johnson et al. | 2019 | Retrospective Single institution |
RFA | Contrast enhancing, nonmetastatic renal mass | Total = 106 Biopsy-proven w/ 10-yr f/u = 39 |
MFS CSS |
Median = 79 months | 10-yr biopsy proven MFS = 94% 10-yr biopsy proven CSS = 94% |
| Zhou et al. | 2019 | Retrospective Single institution | RFA vs PCA vs MWA | Biopsy proven, T1a RCC | RFA cohort = 244 PCA cohort = 26 MWA cohort = 27 |
DFS MFS CSS |
Median = 24 months | 2-yr DFS = 100 vs 100 vs 100% 2-yr MFS = 100 vs 100 vs 100% 2-yr CSS = 100 vs 100 vs 100% |
CSS, cancer-specific survival; DFS, disease-free survival; MFS, Metastasis-free survival; MWA, microwave ablation; OS, overall survival; PCA, percutaneous cryoablation; PN, partial nephrectomy; RCC, renal cell carcinoma; RFA, radiofrequency ablation; RFS, recurrence-free survival.